- Stereotactic radiation therapy (SBRT) does not deteriorate QoL in patients with localized prostate cancer vs active surveillance (AS) at 2 years.
- Conventionally fractionated external beam radiation therapy (EBRT) worsens sexual dysfunction and urinary obstruction/irritation at 3 months and bowel symptoms at 3 and 24 months vs AS.
Why this matters
- Data comparing QoL for patients receiving SBRT vs conventionally fractionated EBRT or AS are insufficient.
- Larger studies with longer follow-up are required to confirm these findings.
- 680 men with newly diagnosed localized prostate cancer received SBRT, EBRT without androgen deprivation therapy, or AS.
- Funding: Patient-Centered Outcomes Research Institute; US Department of Health and Human Services.
- All QoL domain scores in patients who received SBRT were similar to those who received AS at all points (3, 12, and 24 months).
- Patients who received EBRT without ADT vs AS had statistically significantly worse:
- Sexual dysfunction at 3 months (mean difference [MD], 8.0; 95% CI, 0.5-15.6).
- Urinary obstruction and irritation at 3 months (MD, 10.8; 95% CI, 7.5-14.2).
- Bowel scores at 3 months (MD, 4.6; 95% CI, 2.0-7.3) and 24 months (MD, 3.2; 95% CI, 0.2-6.2).
- Nonrandomized trial.
- Small sample size.